We are a long way from psychedelic-assisted therapy being taught in American colleges and Universities. However, that doesn’t mean there...
Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder. The post Cybin Completes Phase 2 Enrollment...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase...
Psilo Scientific, a subsidiary of Filament, will use the leaves to research neuropsychiatric applications. The post Filament Brings Coca Leaves to Canada...
Ahead of World Rivers Day (24 September), new research by the University of Oxford reveals that sewage discharge into rivers has a greater impact on water...
This has been a busy quarter for the psychedelic industry, particularly Lucy Scientific Discovery Inc. The company has announced three acquisitions in...
Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated...
A new study published by researchers from Johns Hopkins shows that psilocybin produces lasting improvements in mental health symptoms and general well-being. The...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...
